A phase II clinical trial (NCT03247088) demonstrated that in advanced pancreatic cancer patients with low dCK expression, the decitabine combination regimen achieved an objective response rate (ORR) of 34%, significantly higher than the 12% observed in the gemcitabine monotherapy group (p = 0.013). The gene discussed is DCK; the disease is pancreatic neoplasm.